Update on the in vitro activity of daptomycin tested against 17,193 gram-positive bacteria isolated from european medical centers (2005-2007)

Journal of Chemotherapy

Volumn 21, Issue 5, 2009, Pages 500-506

  Sader, Helio S ^a   Moet, G ^a   Jones, R N ^a,b  

^a JMI LABORATORIES   (United States)

^b TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Daptomycin; Europe; MRSA; Staphylococcus aureus; Surveillance; VRE

Indexed keywords

AMPICILLIN; CLINDAMYCIN; COTRIMOXAZOLE; DALFOPRISTIN PLUS QUINUPRISTIN; DAPTOMYCIN; ERYTHROMYCIN; GENTAMICIN; LEVOFLOXACIN; LINEZOLID; OXACILLIN; STREPTOMYCIN; TEICOPLANIN; TETRACYCLINE; VANCOMYCIN; ANTIINFECTIVE AGENT;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ANTIMICROBIAL ACTIVITY; ARTICLE; BROTH DILUTION; COAGULASE NEGATIVE STAPHYLOCOCCUS; ENTEROCOCCUS FAECALIS; ENTEROCOCCUS FAECIUM; EUROPE; GEOGRAPHIC DISTRIBUTION; GRAM POSITIVE BACTERIUM; IN VITRO STUDY; IRELAND; ISRAEL; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; SPAIN; STAPHYLOCOCCUS AUREUS; SWEDEN; SWITZERLAND; DRUG EFFECT; GRAM POSITIVE INFECTION; HUMAN; ISOLATION AND PURIFICATION; MICROBIOLOGICAL EXAMINATION; MICROBIOLOGY; UNIVERSITY HOSPITAL;

ACADEMIC MEDICAL CENTERS; ANTI-BACTERIAL AGENTS; DAPTOMYCIN; DRUG RESISTANCE, BACTERIAL; EUROPE; GRAM-POSITIVE BACTERIA; GRAM-POSITIVE BACTERIAL INFECTIONS; HUMANS; METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS; MICROBIAL SENSITIVITY TESTS;

EID: 75549087385     PISSN: 1120009X     EISSN: 19739478     Source Type: Journal    
DOI: 10.1179/joc.2009.21.5.500     Document Type: Article

References (18)

1. Rice LB. Antimicrobial resistance in gram-positive bacteria. Am J Med 2006; 34((5, Suppl 1) S11-S19.
2. MacGowan AP. Clinical implications of antimicrobial resistance for therapy. J Antimicrob Chemother 2008; 62 Suppl 2(ii105-114.
3. NNIS. National Nosocomial Infections Surveillance (NNIS) Systems Report. 2004. Data summary from January 1992 through June 2004, issued October 2004. Am J Infect Control 2004; 32, 8:470-485.
4. Tenover FC, McDougal LK, Goering RV, Killgore G, Projan SJ, Patel JB et al. Characterization of a strain of community-associated methicillin-resistant Staphylococcus aureus widely disseminated in the United States. J Clin Microbiol 2006; 44(1): 108-118.
5. Willems RJ, Top J, van Santen M, Robinson DA, Coque TM, Baquero F, et al. Global spread of vancomycin-resistant En-terococcus faecium from distinct nosocomial genetic complex. Emerg Infect Dis 2005; 11(6):821-828.
6. Werner G, Coque TM, Hammerum AM, Hope R, Hryniewicz W, Johnson A, et al. Emergence and spread of vancomycin resistance among enterococci in Europe. Euro Surveill 2008; 13(47).
7. Eliopoulos GM. Antimicrobial agents for treatment of serious infections caused by resistant Staphylococcus aureus and enterococci. Eur J Clin Microbiol Infect Dis 2005; 24(12):826-831.
8. Arbeit RD, Maki D, Tally FP, Campanaro E, Eisenstein BI. The safety and efficacy of daptomycin for the treatment of complicated skin and skin-structure infections. Clin Infect Dis 2004; 38(12):1673-1681.
9. Fowler VG, Jr, Boucher HW, Corey GR, Abrutyn E, Karchmer AW, Rupp ME, et al. Daptomycin versus standard therapy for bacteremia and endocarditis caused by Staphylococcus aureus. N Engl J Med 2006; 355(7):653-665.
10. EUCAST. The European Committee on Antimicrobial Susceptibility Testing (EUCAST) Steering Committee. EUCAST Technical Note on daptomycin. Clin Microbiol Infect 2006; 12(6):599-601.
11. Levine DP. Clinical experience with daptomycin: bacteraemia and endocarditis. J Antimicrob Chemother 2008; 62 Suppl 3(iii35-39.
12. Seaton RA. Daptomycin: rationale and role in the management of skin and soft tissue infections. J Antimicrob Chemother 2008; 62 Suppl 3(iiil5-23).
13. Sader HS, Streit JM, Fritsche TR, Jones RN. Antimicrobial activity of daptomycin against multidrug-resistant Gram-positive strains collected worldwide. Diagn Microbiol Infect Dis 2004; 50(3):201-204.
14. Hawkey PM. Pre-clinical experience with daptomycin. Journal of Antimicrobial Chemotherapy 2008; 62 Suppl 3 (iii7-14).
15. Sader HS, Streit JM, Fritsche TR, Jones RN. Antimicrobial susceptibility of Gram-positive bacteria isolated from European medical centres: Results of the Daptomycin Surveillance Programme (2002-2004). Clin Microbiol Infect 2006; 12(9):844-852.
16. Clinical and Laboratory Standards Institute. M7-A7, Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically; approved standard - seventh edition. Wayne, PA: CLSI, 2006.
17. Clinical and Laboratory Standards Institute. M100-S18, Performance standards for antimicrobial susceptibility testing, 18th informational supplement. Wayne, PA: CLSI. 2008;
18. Rossolini GM, Mantengoli E. Antimicrobial resistance in Europe and its potential impact on empirical therapy. Clin Microbiol Infect 2008; 14 Suppl 6(2-8.